NASDAQ:PACB - Nasdaq - US69404D1081 - Common Stock - Currency: USD
PACIFIC BIOSCIENCES OF CALIF
NASDAQ:PACB (1/24/2025, 4:04:58 PM)
After market: 1.6992 +0.01 (+0.54%)1.69
+0.04 (+2.42%)
The current stock price of PACB is 1.69 USD. In the past month the price decreased by -16.24%. In the past year, price decreased by -76.5%.
MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions,...
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions,...
Commenced shipment of the Vegaâ„¢ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the...
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 26.82 | 219.87B | ||
DHR | DANAHER CORP | 33.04 | 177.54B | ||
A | AGILENT TECHNOLOGIES INC | 28.63 | 43.19B | ||
IQV | IQVIA HOLDINGS INC | 18.81 | 37.09B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 34.89 | 28.09B | ||
WST | WEST PHARMACEUTICAL SERVICES | 51.04 | 24.98B | ||
WAT | WATERS CORP | 36.11 | 24.42B | ||
ILMN | ILLUMINA INC | 78.74 | 21.60B | ||
ICLR | ICON PLC | 14.29 | 16.55B | ||
AVTR | AVANTOR INC | 22.51 | 15.01B | ||
RVTY | REVVITY INC | 26.04 | 14.99B | ||
TECH | BIO-TECHNE CORP | 43.04 | 12.24B |
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 796 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
PACIFIC BIOSCIENCES OF CALIF
1305 O'brien Drive
Menlo Park CALIFORNIA 94025 US
CEO: Christian O. Henry
Employees: 796
Company Website: https://www.pacb.com/
Investor Relations: https://investor.pacificbiosciences.com
Phone: 16505218000
The current stock price of PACB is 1.69 USD.
The exchange symbol of PACIFIC BIOSCIENCES OF CALIF is PACB and it is listed on the Nasdaq exchange.
PACB stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PACB, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PACB.
PACB does not pay a dividend.
PACB will report earnings on 2025-02-13, after the market close.
PACB does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.46).
The outstanding short interest for PACB is 22.9% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to PACB. Both the profitability and financial health of PACB have multiple concerns.
Over the last trailing twelve months PACB reported a non-GAAP Earnings per Share(EPS) of -1.46. The EPS decreased by -14.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -27.19% | ||
ROE | -87.01% | ||
Debt/Equity | 1.97 |
ChartMill assigns a Buy % Consensus number of 75% to PACB. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of -9.17% and a revenue growth -21.98% for PACB